论文部分内容阅读
目的:观察参芪扶正注射液联合化疗治疗胃癌的临床疗效。方法:将86例胃癌患者随机分为对照组和观察组,对照组给予单纯化疗治疗,观察组给予参芪扶正注射液联合化疗治疗。观察42天。观察2组临床疗效、T细胞亚群的变化情况和不良反应的发生情况。结果:总有效率观察组95.3%,对照组76.7%,2组比较,差异有统计学意义(P<0.05)。治疗后CD3~+、CD4~+、CD8~+、CD4~+/CD8~+观察组与对照组比较,差异均有统计学意义(P<0.05)。恶心呕吐、乏力失眠、白细胞减少Ⅱ度以上、血小板减少Ⅱ度以上观察组与对照组比较,差异均有统计学意义(P<0.05)。结论:参芪扶正注射液联合化疗治疗胃癌的临床效果显著,可显著提高T细胞亚群的活性,缓解和稳定胃癌病灶。
Objective: To observe the clinical efficacy of Shenqi Fuzheng injection combined with chemotherapy in the treatment of gastric cancer. Methods: Eighty-six gastric cancer patients were randomly divided into control group and observation group. The control group was treated with chemotherapy alone. The observation group was treated with Shenqi Fuzheng injection combined with chemotherapy. Observe 42 days. The clinical efficacy, the changes of T cell subsets and the occurrence of adverse reactions in the two groups were observed. Results: The total effective rate was 95.3% in the observation group and 76.7% in the control group. There was significant difference between the two groups (P <0.05). After treatment, the differences of CD3 ~ +, CD4 ~ +, CD8 ~ +, CD4 ~ + / CD8 ~ + between the observation group and the control group were statistically significant (P <0.05). Nausea and vomiting, fatigue, insomnia, leukopenia more than Ⅱ degree, thrombocytopenia Ⅱ degrees above the observation group compared with the control group, the difference was statistically significant (P <0.05). Conclusion: Shenqi Fuzheng injection combined with chemotherapy has a significant clinical effect on gastric cancer, which can significantly increase the activity of T cell subsets and relieve and stabilize gastric cancer.